Search alternatives:
point decrease » point increase (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 point » _ point (Expand Search)
point decrease » point increase (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 point » _ point (Expand Search)
-
861
-
862
Elevated IDO activity in HD mouse brains is decreased by <i>ex-vivo</i> iron chelation.
Published 2021“…<p>Mouse pups were supplemented with carbonyl iron from postnatal days 10–17 and then were sacrificed at 14 weeks of age. <b>A.</b> Striatal IDO activity is increased in N171-82Q HD mice and significantly decreased by <i>ex vivo</i> iron (III) chelation (50 μM deferoxamine). …”
-
863
-
864
-
865
Time-course of changes induced on NCAM and SYN synaptic patterns and levels by glutamate exposure.
Published 2014“…Results are expressed as mean values (±SEM) of 20–30 neurons per experimental condition. ns, non-significant; * P<0.05; ** P<0.01; *** P<0.001 between bars, by Mann-Whitney test. …”
-
866
-
867
Glutamate exposure reduces MAP-2 immunostaining and induces changes in synaptic markers and cell adhesion molecule NCAM in the absence of neuronal death.
Published 2014“…PSA-NCAM immunoreactive area drastically decreased. Results are expressed as mean values (±SEM) of 20-30 neurons or 10 microscope fields (280,000 µm<sup>2</sup>/FOV) per experimental condition. …”
-
868
Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study
Published 2016“…</p><p>Methods</p><p>This study had a cross-sectional case-control design and involved 37 current AAS abusers, 33 former AAS abusers (mean (95%CI) elapsed duration since AAS cessation: 2.5 (1.7; 3.7) years) and 30 healthy control participants. …”
-
869
-
870
Annual number of outpatient visits in recurrence and non-recurrence groups.
Published 2025“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
871
Annual treatment frequencies in all eyes.
Published 2025“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
872
-
873
Annual treatment frequencies in recurrence and non-recurrence groups.
Published 2025“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
-
874
-
875
-
876
-
877
-
878
-
879
-
880